CD39 and CD73 in immunity and inflammation

Luca Antonioli, Pál Pacher, E. Sylvester Vizi, György Haskó

Research output: Contribution to journalReview article

424 Citations (Scopus)


The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ectoenzymes are novel therapeutic targets for managing a variety of disorders.

Original languageEnglish
Pages (from-to)355-367
Number of pages13
JournalTrends in Molecular Medicine
Issue number6
Publication statusPublished - Jun 1 2013


  • CD39
  • CD73
  • Cytokine
  • Ectonucleotidase
  • Macrophage
  • Neutrophil
  • Sepsis
  • Treg

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Fingerprint Dive into the research topics of 'CD39 and CD73 in immunity and inflammation'. Together they form a unique fingerprint.

  • Cite this